2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Pathology, Bioinformatics, Gene Editing, Treatment Considerations, Drug Development, Biological Therapies, Antibody Therapy, Non-Biological Therapies, Pharmacology, Women’s Health, Artificial Intelligence (AI), Biological Processes, Pathogenesis, Hematopoiesis, Metabolism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality Improvement, Diseases, Genetic Disorders, Immunology, Autoimmune Disorders, Metabolic Disorders, Iron Deficiency, Iron Overload, Measurable Residual Disease, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Pregnant, Animal Model
PAPER

1129 One gram does not fit all: Physiology-based iron deficit calculation in pregnancy identifies clinically meaningful variation in intravenous iron requirements.

Mark Chaitowitz, MD, Josette Kamel, MD2
1 Montefiore Medical Center/Albert Einstein College of Medicine, New York, New York, United States
2 Montefiore Medical Center/Albert Einstein College of Medicine, New York, New York, United States

Background

Iron deficiency anemia (IDA) in pregnancy is linked to morbidity in both mothers and neonates. Increased recognition of its prevalence, as well as of concern for the adverse clinical implications of iron deficiency in pregnancy, even in the absence of anemia, had led to a widespread adoption of IVI (intravenous iron), which in this setting effectively, rapidly, and safely replaces iron deficits. However, regarding dosing, despite heterogeneity in this population, a one-size-fits-all approach has been adopted, with patients typically receiving a standardized dose of 1 g of elemental iron, without regard for patient weight or degree of anemia.

Within a cohort of pregnant women with IDA, in whom IVI was indicated, we sought to characterize the distribution of calculated iron deficits (CID), as determined by a mass-balance physiological approach, and determine to what degree CID’s differed from the standard 1g dose. We also sought to determine whether discrepancies in CID’s and administered doses (i.e. underdosing) resulted in suboptimal outcomes.

Method

A retrospective analysis was performed on 148 consecutive pregnant patients referred to e-IRON  - a proprietary EMR-based telemedicine platform for triage and expedited management of iron deficiency – in whom IVI was deemed appropriate. CID’s were calculated using patient weight, hemoglobin, and stage of gestation as inputs. The model assumes a target Hb of 11 g/dL, and unlike the published Ganzoni formula, assumes a gender-appropriate baseline blood volume of 65 ml/kg, which increases linearly during the course of gestation, and is modeled using a piecewise linear approximation. The expansion factor (BV) is defined as: BV = 1.00 for t ≤ 8 weeks, BV = 1 + 0.40 × (t − 8)/28 for 8 < t < 36, BV = 1.40 for t ≥ 36, where t denotes gestational age in weeks. A fixed amount of 500mgs is added, to address depleted iron stores. (A detailed description of the formula, and its assumptions, are viewable at https://idapregcalculator.netlify.app )

Results

The mean and median CID’s were 1106 and 1071 mgs respectively, with an IQR of 297mgs. In 33/148 patient (22%) the CID fell between 1200 and 1400mgs, and in 14/148 (9%) it exceeded 1400 mgs. The mean weight and Hb in this latter group was 100 kg and 7.7 g/dl respectively, versus 79 kg and 9.0 g/dL in those with CIDs below 1400 mg.  

In patients who completed infusions, (n=124) there was a modest but clinically significant correlation (Pearson r=0.209, p=0.0199) between the dose discrepancy, (defined as administered dose less CID), and the Hb at time of delivery. Patients with dose discrepancies < -200 mg (i.e. administered dose >200 mgs lower than CID) had higher rates of anemia (Hb <11g/dl) at delivery (68% vs 51%), corresponding to an odds ratio of 2.07, which did not reach statistical significance (p > 0.05).

In multivariate analysis, the strongest predictor for resolution of anemia was timing of infusion, with each additional day between delivery and infusion reducing odds of anemia by ~3.9% (p < 0.001).


Discussion

In our cohort, a standard dose of 1g was appropriate for the majority of patients but in a subgroup of women, with higher body mass and more severe anemia, the calculated dose may exceed standard dosage by several 100 mg. Nevertheless, while underdosing in our real world cohort did impact Hb at time of delivery, the effect was small and its clinical significance questionable.

We do however note that in this cohort 12/124 patients in fact received 1500 mg, resulting in less ‘underdosing’, and possibly decreased statistical power to detect clinically significant differences, which may have been detected had all patients received the 1g standard.

Otherwise, this study confirms an earlier observation of our group, that early recognition and treatment is the best predictor of success, and clearly overshadows dosing considerations.


Josette Kamel, MD: No relevant conflicts of interest to declare.